4D Molecular Therapeutics, Inc. Investment Income, Interest
4D Molecular Therapeutics, Inc. (FDMT) reported Investment Income, Interest of $4.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $4.25M, a 12.43% decline year-over-year.
- 4D Molecular Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $4.86M, a 12.86% decline year-over-year.
- 4D Molecular Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $4.70M, a 27.26% decline year-over-year.
- 4D Molecular Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $4.33M, a 40.60% decline year-over-year.
- 4D Molecular Therapeutics, Inc. investment income, interest for fiscal 2025 was $19.48M, a 28.00% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. investment income, interest for fiscal 2024 was $27.05M, a 121.52% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. investment income, interest for fiscal 2023 was $12.21M, a 374.58% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. investment income, interest for fiscal 2022 was $2.57M, a 1778.10% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.25M 10-Q · filed 2026-08-13 | $9.12M 10-Q · filed 2026-08-13 | $13.82M derived: sum of 3 quarters · filed 2026-08-13 | $18.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.86M 10-Q · filed 2026-05-07 | $9.57M derived: sum of 2 quarters · filed 2026-05-07 | $13.90M derived: sum of 3 quarters · filed 2026-05-07 | $18.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $9.03M derived: sum of 2 quarters · filed 2026-03-18 | $13.89M derived: sum of 3 quarters · filed 2026-08-13 | $19.48M 10-K · filed 2026-03-18 |
| 2025-09-30 | $4.33M 10-Q · filed 2025-11-10 | $9.19M derived: sum of 2 quarters · filed 2026-08-13 | $14.77M 10-Q · filed 2025-11-10 | $21.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.86M 10-Q · filed 2026-08-13 | $10.44M 10-Q · filed 2026-08-13 | $16.91M derived: sum of 3 quarters · filed 2026-08-13 | $24.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $5.58M 10-Q · filed 2026-05-07 | $12.05M derived: sum of 2 quarters · filed 2026-05-07 | $19.34M derived: sum of 3 quarters · filed 2026-05-07 | $26.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $13.76M derived: sum of 2 quarters · filed 2026-03-18 | $21.30M derived: sum of 3 quarters · filed 2026-03-18 | $27.05M 10-K · filed 2026-03-18 |
| 2024-09-30 | $7.29M 10-Q · filed 2025-11-10 | $14.84M derived: sum of 2 quarters · filed 2025-11-10 | $20.58M 10-Q · filed 2025-11-10 | $24.96M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $7.55M 10-Q · filed 2025-08-11 | $13.29M 10-Q · filed 2025-08-11 | $17.67M derived: sum of 3 quarters · filed 2025-08-11 | $21.55M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $5.75M 10-Q · filed 2025-05-08 | $10.13M derived: sum of 2 quarters · filed 2025-05-08 | $14.00M derived: sum of 3 quarters · filed 2025-05-08 | $16.51M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $8.26M derived: sum of 2 quarters · filed 2025-02-28 | $10.77M derived: sum of 3 quarters · filed 2025-02-28 | $12.21M 10-K · filed 2025-02-28 |
| 2023-09-30 | $3.88M 10-Q · filed 2024-11-13 | $6.39M derived: sum of 2 quarters · filed 2024-11-13 | $7.83M 10-Q · filed 2024-11-13 | $9.17M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.51M 10-Q · filed 2024-08-08 | $3.96M 10-Q · filed 2024-08-08 | $5.29M derived: sum of 3 quarters · filed 2024-08-08 | $6.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.44M 10-Q · filed 2024-05-09 | $2.78M derived: sum of 2 quarters · filed 2024-05-09 | $3.58M derived: sum of 3 quarters · filed 2024-05-09 | $3.92M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.13M derived: sum of 2 quarters · filed 2024-02-29 | $2.47M derived: sum of 3 quarters · filed 2024-02-29 | $2.57M 10-K · filed 2024-02-29 |
| 2022-09-30 | $795.00K 10-Q · filed 2023-11-09 | $1.14M derived: sum of 2 quarters · filed 2023-11-09 | $1.24M 10-Q · filed 2023-11-09 | $923.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $340.00K 10-Q · filed 2023-08-09 | $440.00K 10-Q · filed 2023-08-09 | $128.00K derived: sum of 3 quarters · filed 2023-08-09 | $563.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-11 | -$212.00K derived: sum of 2 quarters · filed 2023-05-11 | $223.00K derived: sum of 3 quarters · filed 2023-05-11 | $230.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $123.00K derived: sum of 2 quarters · filed 2023-03-15 | $130.00K derived: sum of 3 quarters · filed 2023-03-15 | $137.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $435.00K 10-Q · filed 2022-11-08 | $442.00K derived: sum of 2 quarters · filed 2022-11-08 | $449.00K 10-Q · filed 2022-11-08 | $453.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $7.00K 10-Q · filed 2022-08-11 | $14.00K 10-Q · filed 2022-08-11 | $18.00K derived: sum of 3 quarters · filed 2022-08-11 | $22.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $7.00K 10-Q · filed 2022-05-12 | $11.00K derived: sum of 2 quarters · filed 2022-05-12 | $15.00K derived: sum of 3 quarters · filed 2022-05-12 | $29.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $8.00K derived: sum of 2 quarters · filed 2022-03-28 | $22.00K derived: sum of 3 quarters · filed 2022-03-28 | $152.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $4.00K 10-Q · filed 2021-11-10 | $18.00K derived: sum of 2 quarters · filed 2021-11-10 | $148.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $14.00K 10-Q · filed 2021-08-12 | $144.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $130.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $1.50M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |